Cargando…
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
Mutations in subunits of the SWItch Sucrose Non-Fermentable (SWI/SNF) complex occur in 20% of all human tumors. Among these, the core subunit SMARCB1 is the most frequently mutated, and SMARCB1 loss represents a founder driver event in several malignancies, such as malignant rhabdoid tumors (MRT), e...
Autores principales: | Ngo, Carine, Postel-Vinay, Sophie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945563/ https://www.ncbi.nlm.nih.gov/pubmed/35327458 http://dx.doi.org/10.3390/biomedicines10030650 |
Ejemplares similares
-
SMARCB1/INI1-deficient tumors of adulthood
por: Parker, Nathaniel A., et al.
Publicado: (2020) -
Beyond SMARCB1 Loss: Recent Insights into the Pathobiology of Epithelioid Sarcoma
por: Del Savio, Elisa, et al.
Publicado: (2022) -
SMARCB1(INI1)-deficient Sinonasal Basaloid Carcinoma: A Novel Member of the Expanding Family of SMARCB1-deficient Neoplasms
por: Agaimy, Abbas, et al.
Publicado: (2014) -
SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities
por: Cooper, Garrett W., et al.
Publicado: (2022) -
Oncogenic roles of SMARCB1/INI1 and its deficient tumors
por: Kohashi, Kenichi, et al.
Publicado: (2017)